The GH-IGF-I axis and breast cancer

Trends in Endocrinology and Metabolism

Volumn 14, Issue 1, 2003, Pages 28-34

  Laban, Christiana ^a   Bustin, Stephen A ^b   Jenkins, Paul J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CATHEPSIN D; COMPLEMENTARY RNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; OCTREOTIDE; PEGVISOMANT; PROGESTERONE RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TYROSINE; VASCULOTROPIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER RISK; DRUG RESISTANCE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; ESTROGENS; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; TAMOXIFEN;

EID: 0038069319     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(02)00003-6     Document Type: Review

References (70)

1. Mauro, L. et al. (2001) IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J. Biol. Chem. 276, 39892-39897
2. Glondu, M. et al. (2002) Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21, 5127-5134
3. Xie, W. et al. (2001) Activation of adenosine deaminase in MCF-7 cells through IGF-estrogen receptor α crosstalk. J. Mol. Endocrinol. 26, 217-228
4. Ng, S.T. et al. (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat. Med. 3, 1141-1144
5. Ruan, W. and Kleinberg, D.L. (1999) Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140, 5075-5081
6. Hadsell, D.L. et al. (1996) Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137, 321-330
7. Peyrat, J.P. et al. (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer 29A, 492-497
8. Hankinson, S.E. et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351, 1393-1396
9. Kaaks, R. et al. (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Contr. 13, 307-316
10. Yu, H. et al. (2001) Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res. Treat. 70, 117-122
11. Missmer, S.A. et al. (2002) A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int. J. Cancer 100, 332-336
12. Gooch, J.L. et al. (1999) Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res. Treat. 56, 1-10
13. Tornell, J. et al. (1992) High frequency ofmammary adenocarcinomas in metallothionein promoter human growth hormone transgenic mice created from two different strains of mice. J. Steroid Biochem. Mol. Biol. 43, 237-242
14. Bates, P. et al. (1995) Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer 72, 1189-1193
15. Arteaga, C.L. et al. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest. 84, 1418-1423
16. Yang, X.F. et al. (1996) Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 56, 1509-1511
17. Mol, J.A. et al. (1995) Expression of the gene encoding growth hormone in the human mammary gland. J. Clin. Endocrinol. Metab. 80, 3094-3096
18. Mertani, H.C. et al. (1998) Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer 79, 202-211
19. Gebre-Medhin, M. et al. (2001) Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 158, 1217-1222
20. Yee, D. et al. (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol. 3, 509-517
21. Paik, S. (1992) Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res. Treat. 22, 31-38
22. Ellis, M.J. et al. (1994) Insulin-like growth factor mediated stromalepithelial interactions in human breast cancer. Breast Cancer Res. Treat. 31, 249-261
23. Eppler, E. et al. (2002) IGF-I in human breast cancer: low differentiation stage is associated with decreased IGF-I content. Eur. J. Endocrinol. 146, 813-821
24. Heffelfinger, S.C. et al. (1999) Angiogenic growth factors in preinvasive breast disease. Clin. Cancer Res. 5, 2867-2876
25. Surmacz, E. et al. (1998) Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res. Treat. 47, 255-267
26. Resnik, J.L. et al. (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 58, 1159-1164
27. Jammes, H. et al. (1992) Insulin-like growth factor I receptors in human breast tumour: localisation and quantification by histoautoradiographic analysis. Br. J. Cancer 66, 248-253
28. Peyrat, J.P. et al. (1990) Insulin-like growth factor I receptors (IGFI-R) and IGF-I in human breast tumors. J. Steroid Biochem. Mol. Biol. 37, 823-827
29. Pekonen, F. et al. (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res. 52, 5204-5207
30. Figueroa, J.A. et al. (1993) Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J. Cell. Biochem. 52, 196-205
31. Helle, S.I. and Lonning, RE. (1996) Insulin-like growth factors in breast cancer. Acta Oncol. 35 (Suppl. 5), 19-22
32. Cohick, W.S. et al. (2000) Insulin-like growth factor I (IGF-I) and cyclic adenosine 3′,5′-monophosphate regulate IGF-binding protein-3 gene expression by transcriptional and posttranscriptional mechanisms in mammary epithelial cells. Endocrinology 141, 4583-4591
33. Oh, Y. et al. (1993) Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 268, 26045-26048
34. Fowler, C.A. et al. (2000) Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int. J. Cancer 88, 448-453
35. Kahan, Z. et al. (1999) Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J. Clin. Endocrinol. Metab. 84, 582-589
36. Benlot, C. et al. (1997) Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation. J. Clin. Endocrinol. Metab. 82, 690-696
37. Rekasi, Z. et al. (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc. Natl Acad. Sci. USA 97, 10561-10566
38. Szepeshazi, K. et al. (2001) Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142, 4371-4378
39. Cassoni, P. et al. (2001) Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 86, 1738-1745
40. Schaer, J.C. et al. (1997) Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int. J. Cancer 70, 530-537
41. Evans, A.A. et al. (1997) Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br. J. Cancer 75, 798-803
42. Chen, A. et al. (1999) Selective expression of neuropeptides in the rat mammary gland: somatostatin gene is expressed during lactation. Endocrinology 140, 5915-5921
43. Guvakova, M.A. and Surmacz, E. (1997) Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 57, 2606-2610
44. Bonanni, B. et al. (2001) Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Res. Treat. 69, 21-27
45. Tannenbaum, G.S. et al. (1992) Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130, 3395-3401
46. Huynh, H.T. et al. (1993) In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 53, 1727-1730
47. Campbell, M.J. et al. (2001) IGF status is altered by tamoxifen in patients with breast cancer. Mol. Pathol. 54, 307-310
48. Ruan, W. et al. (1995) Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 136, 1296-1302
49. Stewart, A.J. et al. (1990) Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265, 21172-21178
50. Rochefort, H. (1994) Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur. J. Cancer 30A, 1583-1586
51. Lee, A.V. et al. (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 13, 787-796
52. Migliaccio, A. et al. (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15, 1292-1300
53. Ahmad, S. et al. (1999) Role of AKT1 in 17β-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol. 58, 425-430
54. Stoica, A. et al. (2000) Regulation of estrogen receptor-α gene expression by epidermal growth factor. J. Endocrinol. 165, 371-378
55. Lee, A.V. et al. (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol. 152, 39-47
56. Wong, S.F. et al. (2001) Effect of transforming growth factor-β1, insulin-like growth factor-I and insulin-like growth factor-II on cell growth and oestrogen metabolism in human breast cancer cell lines. Pathology 33, 454-459
57. Dunn, S.E. et al. (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58, 3353-3361
58. Neuenschwander, S. et al. (1995) Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136, 4298-4303
59. Wen, B. et al. (2001) Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br. J. Cancer 85, 2017-2021
60. Yee, D. et al. (1994) Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ. 5, 73-77
61. Weckbecker, G. et al. (1992) Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 41, 99-103
62. O'Byrne, K.J. et al. (1999) Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br. J. Cancer 79, 1413-1418
63. Ingle, J.N. et al. (1999) A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85, 1284-1292
64. Bajetta, E. et al. (2002) A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94, 299-304
65. Bontenbal, M. et al. (1998) Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br. J. Cancer 77, 115-122
66. Friend, K.E. (2001) Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm. IGF Res. 11, S121-S123
67. Nicholson, R.I. and Gee, J.M. (2000) Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer 82, 501-513
68. Lu, Y. et al. (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93, 1852-1857
69. Balana, M.E. et al. (2001) Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20, 34-47
70. Albanell, J. and Baselga, J. (2001) Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J. Natl Cancer Inst. 93, 1830-1832